Print Page  Close Window    

Investor Relations Home

Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Featured Documents

06/16/18A Phase 1, Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of LJPC-401
06/16/18EHA Poster
12/22/17GIAPREZA™ (angiotensin II) Update

Share Price

Stock chart for: LJPC.OQ.  Currently trading at $7.26 with a 52 week high of $38.39 and a 52 week low of $5.01.
Price$7.26
Change (%) Stock is Down 0.12 (1.63%)
Volume142,750
Data as of 03/20/19 3:01 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.


Upcoming Events




There are currently no events scheduled.

Recent News


La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer

03/11/19

SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference

03/07/19

SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives

03/04/19

SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from

Read More